Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Urges Trump Not To Destabilize Supply Chain

Warns ‘Buy American’ Changes Could Hinder COVID-19 Pandemic Response

Executive Summary

The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.

You may also be interested in...



Purchasing Commitments Must Underpin US Expansion

In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.

Supply Chain Truce In COVID-19: Will It Carry Over When Rx Price Debate Resumes?

Manufacturers, insurers, pharmacies and PBMs are united in trying to assure ongoing access to medicines amid the COVID-19 outbreak. Will making common cause in a national emergency mean a more cooperative approach to addressing US drug pricing concerns when normalcy returns?

AAM Urges Diverse Supply Chain To Mitigate Future Crises

The AAM has outlined a set of principles that it says will help protect patient access to generics and biosimilars and aid in efforts to diversify the supply chain to help mitigate future crises. The association said it would work with policymakers and other stakeholders to formulate policies to address concerns that the coronavirus pandemic has raised.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel